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SCIENCE 
CATALANS SHAPING 
BIOMEDICAL RESEARCH 
IN NORTH AMERICA 
IN THE SECOND HALF OF THE 2 0 ~ ~  CENTURY, AN INCREASING 
INFLUX OF CATALANS HAVE ARRIVED IN THE USA AND CANADA, 
SINCE AFTER THE SECOND WORLD WAR AMERICA TOOK 
GERMANY'S PLACE AS THE COUNTRY WITH MOST RESOURCES 
AVAILABLE FOR RESEARCH AND WHERE THE PRESENCE OF ' 
LEADING SCIENTISTS OFFERS OPPORTUNITIES FOR ADVANCED 
TRAINING AND SUBSEQUENT DEVELOPMENT AS INDEPENDENT 
SCIENTISTS . 
A N G E L  P E L L I C E R  D E P A R T M E N T  O F  P A T H O L O G Y .  
N E W  Y O R K  U N I V E R S I T Y  
he irnpact of Catalans in the field 
of biomedical research has been 
widespread and has reached 
rnany different areas. We shall concen- 
trate here on a few subiects in which a 
nurnber of investigators have rnade irn- 
portant contributions. These areas are 
Biochernistry, Oncology, Nutrition, Car- 
diovascular Pathophysiology, Physical Re- 
habilitation and Health Policy and Corn- 
rnunity Medicine. 
In the area of basic biocherni~tr~, Dr Joan 
Oró, at the University of Houston, has 
produced pioneering work designing ex- 
perimental conditions to rnirnic the pre- 
biotic atmosphere and has rnanaged to 
obtain rnany of the simple molecules that 
represent the building blocks of the corn- 
plex polyrners forrning living cells. This 
research has shown that chemical reac- 
tions could account for the assernbling of 
molecules thought to be exclusive to living 
processes. Dr Oró also collaborated with 
NASA in the analysis of the sarnples 
brought back frorn Mars, and his conclu- 
sions indicated that there i s  no trace of 
organic rnolecules consistent with the 
existence of life on that planet. 
Continuing in basic biochernistry, Dr 
Adolfo Ruiz Carrillo, at the Hotel-Dieu in 
Quebec, has rnade significant contribu- 
tions to the structure of chromatin, the nu- 
cleoprotein cornplex containing the genet- 
ic information in eukaryotic cells. These 
studies have contributed to an under- 
standing, first, of how the cornponents 
are assembled, a necessary step to un- 
derstanding how the different elements 
rnodulate gene expression, the process 
that ultimately controls embryonic de- 
veloprnent, tissue differentiation and cell 
proliferation. 
Analysis of the basic processes of signal 
transduction has been the obiect of work 
by Dr Joan Codina, a rnaior contributor 
to the study of G proteins. He has been 
involved in the process of their biochern- 
ical characterization, purification and 
subsequent deterrnination of very different 
biological pathways that are rnediated by 
this farnily of proteins. 
In the field of cancer a sizable nurnber of 
Catalans have contributed significantly to 
understanding the rnolecular basis of the 
disease, its clinical correlates and thera- 
peutic approaches. In the rnolecular ba- 
sis of cell proliferation Dr Angel Pellicer, 
of New York University, has contributed 
to the identification of oncogenes as the 
subset of genes that are altered in the 
process of tumor developrnent, thus pro- 
viding a genetic underpinning to the pro- 
cess. Dr Joan Massagué, of Memorial 
Sloan-Kettering, New York, has been a 
pioneer in the identification of factors that 
repress cell proliferation and has uncov- 
ered their receptors and several steps in 
their signal transduction. 
Dr Pere Gascon, of the College of Medi- 
cine and Dentistry, Newark, has studied 
stern cell proliferation in normal and rna- 
lignant haernopoietic cells. He has pio- 
neered studies of the neuropeptide effects 
on haemopoiesis. Dr Carles Cordon Car- 
do, of Memorial Sloan-Kettering, New 
York, has provided a correlation be- 
tween the expression of oncogenes and 
tumor suppressor genes, their pathological 
rnanifestations and the clinical outcorne, 
providing useful rnolecular prognostic 
rnarkers. Dr Josep Costa, at Yale Univer- 
sity, New Haven, has analyzed colon 
cancer, both at the morphological and at 
the rnolecular level, uncovering rnolecular 
clues to this disease. 
In the therapeutic field, Dr Lluis Delclós, 
of the Anderson Cancer Center in Hous- 
ton, has designed and led studies in the 
successful radiation treatrnent of several 
gynaecological cancers that do not re- 
spond to other treatrnents. Dr Alfred Giner 
Sorolla, of the University of Southern Flo- 
rida, Tarnpa, has rnade very significant 
contributions to the design and biochern- 
ical analysis of chernotherapeutic drugs. 
Dr Rornan Perez i Soler, also at the An- 
derson Cancer Center in Houston, has 
concentrated his efforts on irnproving the 
delivery systerns for chemotherapeutic 
drugs, specifically using liposornes. 
In the field of nutrition, Dr Francesc Xa- 
vier Pisunyer of Columbia University, 
New York, has rnade an irnportant con- 
tribution in the rnanagernent of caloric in- 
take to rnaintain good health and in the 
pathophysiology of diabetes, and i s  cur- 
rently president of the Arnerican Diabetes 
Association. 
In the clinical and experimental aspects 
of atherosclerosis and one of its rnost fa- 
tal consequences, rnyocardial infarction, 
Dr Valentí Fuster, at the Mount Sinai 
Medical Center in New York, i s  an inter- 
national authority who has established 
animal rnodel systerns for the disease and 
at the sarne time has contributed signifi- 
cantly to the role of platelets in the pro- 
cess. 
Dr David Cardús, at the Baylor College 
of Medicine, Houston, has been involved 
in designing rational treatrnent for spinal 
cord iniuries and has evolved towards 
pioneering rnathernatical and cornputer 
treatrnent of biological problerns, espe- 
cially in rehabilitation and gravitational 
stress. 
Dr Carles Vallbona of the Baylor Hospi- 
tal in Houston has been involved in set- 
ting up changes that have created Corn- 
rnunity Medicine as a separate specialty, 
designing new prograrns for hypertension 
and diabetes awareness that have won 
widespread acclairn. Dr Vicenq Navarro, 
at the Johns Hopkins University in Balti- 
more, i s  a leading authority on health 
policy and has approached with foresight 
the problern of public versus private 
health care and the formulas to control 
escalating health care costs. 4 
